最近,水性胶束介质中的光催化为激活强碳卤键开辟了广阔的途径。然而,到目前为止,它主要探索了强烈的还原条件,将可用的化学空间限制为自由基或阴离子反应性。在这里,我们展示了一种可控的光催化策略,该策略通过自由基或阳离子途径引导氯化苯甲酰胺的反应,从而实现化学发散的 C-H 芳基化或N-脱烷基化。该催化系统在温和的条件下运行,亚甲基蓝作为光催化剂,蓝色 LED 作为光源。介绍了决定底物反应性、选择性和初步机理研究的因素。
METHOD FOR THE CATALYTIC REDUCTION OF ACID CHLORIDES AND IMIDOYL CHLORIDES
申请人:Nikonov Georgii
公开号:US20140228579A1
公开(公告)日:2014-08-14
The present application relates to methods for the catalytic reduction of acid chlorides and/or imidoyl chlorides. The methods comprise reacting the acid chloride or imidoyl chloride with a silane reducing agent in the presence of a catalyst such as [Cp(Pr
i
3
P)Ru(NCMe)
2
]
+
[PF
6
]
−
.
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
申请人:Rodgers D. James
公开号:US20070135461A1
公开(公告)日:2007-06-14
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
AMINOQUINOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
申请人:YOO Kyung-Ho
公开号:US20100249182A1
公开(公告)日:2010-09-30
Provided are a novel aminoquinoline compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, preparation method thereof, and a pharmaceutical composition for preventing or treating cutaneous cancer, comprising the aminoquinoline compound or pharmaceutically acceptable salt thereof. Since the compound of Formula 1 exhibits excellent anti-proliferative effect on melanoma tumor cells, it is useful for preventing or treating cutaneous cancer.
wherein R
1
, R
2
, and R
3
are defined in the specification.
HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
申请人:Rodgers James D.
公开号:US20090181959A1
公开(公告)日:2009-07-16
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.